Vaccines for colorectal cancer and renal cell carcinoma

Cancer Journal

Volumn 17, Issue 5, 2011, Pages 283-293

  Kabaker, Katherine ^a   Shell, Kathryn ^a   Kaufman, Howard L ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Clinical trial; colorectal cancer; renal cell carcinoma; treatment; vaccine

Indexed keywords

BCG VACCINE; CANCER VACCINE; CARBONATE DEHYDRATASE IX; CARCINOEMBRYONIC ANTIGEN; EDRECOLOMAB; FLUOROURACIL; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA ANTIGEN; MODIFIED VACCINIA VIRUS ANKARA 5T4 VACCINE; MUCIN 1; NY ESO 1 ANTIGEN; PLACEBO; PROTEIN P53; TUMOR CELL VACCINE;

ADVANCED CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; COLON ADENOCARCINOMA; COLON CANCER; COLORECTAL CANCER; FOLLOW UP; FOWLPOX VIRUS; HUMAN; KIDNEY CARCINOMA; METASTASIS; MONOTHERAPY; PRIORITY JOURNAL; REVIEW; VACCINIA VIRUS; VIRUS RECOMBINANT;

ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; CARCINOEMBRYONIC ANTIGEN; CARCINOMA, RENAL CELL; CLINICAL TRIALS AS TOPIC; COLORECTAL NEOPLASMS; HUMANS; KIDNEY NEOPLASMS; MICE; MICE, TRANSGENIC; MUCIN-1; VACCINES, DNA;

EID: 80053370602     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0b013e318232ff44     Document Type: Review

References (92)

1. Kenter GG, Welters MJP, Valentin ARPM, et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med. 2009;361:1838-1847.
2. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363:411-422.
3. Sang M, Wang L, Ding C, et al. Melanoma-associated antigen genesV an update. Cancer Lett. 2011;302:85-90.
4. Kim PS, Ahmed R. Features of responding T cells in cancer and chronic infection. Curr Opin Immunol. 2010;22:223-230.
5. American Cancer Society. Colorectal Cancer Facts and Figures 2011-2013. Atlanta, GA: American Cancer Society; 2011.
6. Hurwitz H, Fehrenbacher L, Novotny, W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colon cancer. N Engl J Med. 2004;350:2335-2342. (Pubitemid 38702844)
7. Kabbinavar FF, Hambleton J, Mass RD, et al. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol. 2005;23:3706-3712.
8. Allegra CJ, Yothers G, OConnell MJ, et al. Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP Protocol C-08. J Clin Oncol. 2011;29:11-16.
9. Allegra CJ, Jessup JM, Somerfield MR, et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol. 2009;27:2091-2096.
10. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;351:337-345. (Pubitemid 38944402)
11. Van Cutsem E, Köhne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009; 360:1408-1417.
12. Foon KA, John WJ, Chakraborty M, et al. Clinical and immune responses in resected colon cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics the carcinoembryonic antigen. J Clin Oncol. 1999;17:2889-2895. (Pubitemid 29415249)
13. Marshall JL, Hoyer RJ, Toomey MA, et al. Phase I study in advanced cancer patients of a diversified prime and boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses. J Clin Oncol. 2000;18:3964-3973.
14. von Mehren M, Arlen P, Tsang KY, et al. Pilot study of a dual gene recombinant avipox vaccine containing both carcinoembryonic antigen (CEA) and B7.1 transgenes in patients with recurrent CEA-expressing adenocarcinomas. Clin Cancer Res. 2000;6:2219-2228. (Pubitemid 30399187)
15. Kaufman HL, Lenz HJ, Marshall J, et al. Combination chemotherapy and ALVAC-CEA/B7.1 vaccine in patients with metastatic colorectal cancer. Clin Cancer Res. 2008;14:4843-4849.
16. Marshall JL, Gulley JL, Arlen PM, et al. Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocytemacrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas. J Clin Oncol. 2005;23:720-731. (Pubitemid 46224171)
17. Gulley JL, Arlen PM, Tsang KY, et al. Pilot study of vaccination with recombinant CEA-MUC-1-TRICOMpoxviral-based vaccines in patients with metastatic carcinoma. Clin Cancer Res. 2008;14:3060-3069.
18. Lou E, Marshall J, Aklilu M, et al. A phase II study of active immunotherapy with PANVAC or autologous, cultured dendritic cells infected with PANVAC after complete resection of hepatic metastases of colorectal carcinoma. Clin Colorectal Cancer. 2006;5:368-371. (Pubitemid 43280069)
19. Goydos JS, Elder E, Whiteside TL, et al. A phase I trial of a synthetic mucin peptide vaccine. J Surg Res. 1996;63:298-304.
20. Karanikas V, Hwang L, Pearson J, et al. Antibody and T cell responses of patients with adenocarcinoma immunized with mannan-MUC1 fusion protein. J Clin Invest. 1997;100:2783-2792. (Pubitemid 28007547)
21. Robins RA, Denton GW, Hardcastle JD, et al. Antitumor immune response and interleukin 2 production induced in colorectal cancer patients by immunization with human monoclonal anti-idiotypic antibody. Cancer Res. 1991;51:5425-5429.
22. Maxwell-Armstrong CA, Durrant LG, Buckley TJD, et al. Randomized double-blind phase II survival study comparing immunization with the anti-idiotypic monoclonal antibody 105AD7 against placebo in advanced colorectal cancer. Br J Cancer. 2001;84:1443-1446. (Pubitemid 32579332)
23. Carbone DP, Ciernik IF, Kelley MJ, et al. Immunization with mutation p53- and K-ras- derived peptides in cancer patients: immune response and clinical outcomes. J Clin Oncol. 2005;23:5099-5107. (Pubitemid 46224018)
24. Speetjens FM, Kuppen PJK,Welters MJP, et al. Induction of p-53 specific immunity by a p53 synthetic long peptide vaccine in patients treated for metastatic colorectal cancer. Clin Cancer Res. 2009;15:1086-1095.
25. Habal N, Gupta RK, Bilchik AJ, et al. CancerVax, an allogeneic tumor cell vaccine, induced specific humoral and cellular immune responses in advanced colon cancer. Ann Surg Oncol. 2001;8:389-401. (Pubitemid 32524761)
26. Miyagi Y, Imai N, Sasatomi T, et al. Induction of cellular immune responses to tumor cells and peptides in colorectal cancer patients by vaccination with SART3 peptides. Clin Cancer Res. 2001;7:3950-3962. (Pubitemid 34044613)
27. Khleif SN, Abrams SI, Hamilton JM, et al. A phase I vaccine trial with peptides reflecting ras oncogene mutations of solid tumors. J Immunother. 1999;22:155-165. (Pubitemid 29135900)
28. Toubaji A, Achtar M, Provenzano M, et al. Pilot study of mutant ras peptide-based vaccine as an adjuvant treatment in pancreatic and colorectal cancers. Cancer Immunol Immunother. 2008;57:1413-1420.
29. Harrop R, Drury N, Shingler W, et al. Vaccination of colorectal cancer patients with modified vaccinia Ankara encoding the tumor antigen 5T4 (TroVax) given alongside chemotherapy induces potent immune responses. Clin Cancer Res. 2007;13:4487-4494. (Pubitemid 47219718)
30. Moulton HM, Yoshihara PH, Mason DH, et al. Active specific immunotherapy with A-human chorionic gonadotropin peptide vaccine in patients with colorectal cancer. Clin Cancer Res. 2002;8:2044-2051.
31. Tsuruma T, Hata F, Torigoe T, et al. Phase I clinical study of antiapoptosis protein, surviving-derived peptide vaccine therapy for patients with advanced or recurrent colorectal cancer. J Trans Med. 2004;2: 19-29.
32. Di Giorgio A, Botti C, Tocchi A, et al. The influence of tumor lymphocytic infiltration on long term survival of surgically treated colorectal cancer patients. Int Surg. 1992;77:256-260.
33. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277.
34. Hock LM, Lynch J, Balagi KC, et al. Increasing incidence of all stages of kidney cancer in the last 2 decades in the United States: an analysis of surveillance, epidemiology and end results program data. J Urol. 2002;167:57-60. (Pubitemid 34024497)
35. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin. 2004;54:8-29. (Pubitemid 38443417)
36. Hawkins RE, Macdermott C, Shablak A, et al. Vaccination of patients with metastatic renal cell cancer with modified vaccinia Ankara encoding the tumor antigen 5T4 (TroVax) given alongside interferon-alpha. J Immunother. 2009;32:424-429.
37. Amato RJ, Shingler W, Naylor S, et al. Vaccination of renal cell cancer patients with modified vaccinia Ankara delivering tumor antigen 5T4 (TroVax) administered with interleukin-2: a phase II trial. Clin Cancer Res. 2008;14:7504-7510.
38. Kaufman HL, Taback B, Sherman W, et al. Phase II trial of modified vaccinia Ankara (MVA) virus expressing 5T4 and high dose interleukin- 2 (IL-2) in patients with metastatic renal cell carcinoma. J Transl Med. 2009;7:2.
39. Amato RJ, Shingler W, Goonewardena M, et al. Vaccination of renal cell cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) alone or administered in combination with interferonalpha (IFNalpha): a phase 2 trial. J Immunother. 2009;32:765-772.
40. Amato RJ, Hawkins R, Kaufman HL, et al. Vaccination of metastatic renal cancer patients with MVA-5T4: a randomized, double-blind, placebocontrolled phase III study. Clin Cancer Res. 2010;16:5539-5547.
41. Bolhassani A, Safaiyan S, Rafati S. Improvement of different vaccine delivery system for cancer therapy. Mol Cancer. 2011;10:3-22.
42. Bodles-Brakhop AM, Draghia-Aki R. DNA vaccination and gene therapy: optimization and delivery for cancer therapy. Exp Rev Vaccines. 2008;7:1085-1101.
43. Binder RJ. Heat-shock protein-based vaccines for cancer and infectious diseases. Exp Rev Vaccines. 2008;7:383-393. (Pubitemid 351520026)
44. Shurin MR, Gregory M, Morris JC, et al. Genetically modified dendritic cells in cancer immunotherapy: a better tomorrow? Exp Opin Biol Ther. 2010;10:1539-1553.
45. Wagener C, Petzold P, Kohler W, et al. Binding of five monoclonal anti- CEA antibodies with different epitope specificities to various carcinoma tissues. Int J Cancer. 1984;33:469-475. (Pubitemid 14142423)
46. Shively JE, Beatty JD. CEA-related antigens: molecular biology and clinical significance. Crit Rev Oncol Hematol. 1985;2:355-399.
47. Thompson J, Zimmerman W. The carcinoembryonic antigen gene family: structure, expression and evolution. Tumor Biol. 1988;9:63-83.
48. Benchimol S, Fuks A, Jothy S, et al. Carcinoembryonic antigen, a human tumor marker, functions as an intercellular adhesion molecule. Cell. 1989;57:327-334. (Pubitemid 19112371)
49. Hodge JW, Poole DJ, Aarts WM, et al. Modified vaccinia virus Ankara recombinants are as potent as vaccinia recombinants in diversified prime and boost vaccine regimens to elicit therapeutic antitumor responses. Cancer Res. 2003;63:7942-7949. (Pubitemid 37466731)
50. Campos E, Palacin A, Benasco C, et al Human chorionic gonadotropin in colorectal carcinoma an immunohistochemical study. Cancer. 1987; 59:1611-1616. (Pubitemid 17060105)
51. Hole N, Stern PL. A 72 kD trophoblast glycoprotein defined by a monoclonal antibody. Br J Cancer. 1988;57:239-246. (Pubitemid 18096328)
52. Starzynska T, Rahi V, Stern PL. The expression of 5T4 in colorectal and gastric carcinoma. Br J Cancer. 1992;66:867-869.
53. Starzynska T, Marsh PJ, Schofield PF, et al. Prognostic significance of 5T4 oncofetal antigen expression in colorectal carcinoma. Br J Cancer. 1994;69:899-902. (Pubitemid 24140671)
54. Harrop R, Connolly N, Redchenko I, et al. Vaccination of colorectal cancer patients with modified vaccinia Ankara delivering tumor antigens 5T4 (TroVax) induces immune responses which correlate with disease control: a phase I/II trial. Clin Cancer Res. 2006;12:3416-3424.
55. Elkord E, Dangoor A, Drury NL, et al. An MVA-based vaccine targeting the oncofetal antigen 5T4 in patients undergoing surgical resection of colorectal cancer metastases. J Immunother. 2008;31:820-829.
56. Kawasaki H, Altieri DC, Lu C, et al Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res. 1998;58: 5071-5074. (Pubitemid 28521163)
57. Sarela AI, Macadam RCA, Farmery SM, et al. Expression of the antiapoptosis gene, survivin, predicts death from recurrent colorectal carcinoma. Gut. 2000;46:645-650. (Pubitemid 30305781)
58. Barratt-Boyes SM. Making the most of mucin: a novel target for tumor immunotherapy. Cancer Immunol Immunother. 1996;43:142-151. (Pubitemid 26417594)
59. Brayman M, Thathiah A, Carson DD. MUC1: a multifunctional cell surface component of reproductive tissue epithelia. Reprod Biol Endocrinol. 2004;2:4-12.
60. Finn OJ, Jerome KR, Henderson RA, et al. MUC-1 epithelial tumor mucinbased immunity and cancer vaccines. Immunol Rev. 1995;145:61-89.
61. Durrant LG, Chapman MA, Buckley DJ, et al. Enhanced expression of the complement regulatory protein CD55 predicts poor prognosis in colorectal cancer patients. Cancer Immunol Immunother. 2003;52:638-642. (Pubitemid 37268197)
62. Spendlove I, Li L, Carmichael J, et al. Decay accelerating factor (CD55); a target for vaccines? Cancer Res. 1999;59:2282-2286. (Pubitemid 29242268)
63. Fields ALA, Keller A, Schwartzberg L, et al. Adjuvant therapy with the monoclonal antibody. Edrecolomab plus fluorouracil-based therapy does not improve overall survival of patients with stage III colon cancer. J Clin Oncol. 2009;27:1941-1947.
64. Reithmü ller G, Holz E, Schlimok G, et al. Monoclonal antibody therapy for resected Dukes C colorectal cancer: seven-year outcome of a multicenter randomized trial. J Clin Oncol. 1998;16:1788-1794.
65. Ragnhammer P, Fagerberg J, Frodin J, et al. Effect of monoclonal antibody 17-1A and gm-CSF in patients with advanced colorectal carcinomalong lasting, complete remissions can be induced. Int J Cancer. 1993; 53:751-758. (Pubitemid 23100116)
66. Nigro JM, Baker SJ, Preisinger AC, et al. Mutations in the p53 gene occur in diverse human tumour types. Nature. 1989;342:705-708. (Pubitemid 20001591)
67. Van Den Berg FM, Tigges AJ, Schipper MEI, et al. Expression of the nuclear oncogene p53 in colon tumours. J Pathol. 1989;157:193-199. (Pubitemid 19076350)
68. Russo A, Bazan A, Lacopetta B, et al. The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment. J Clin Oncol. 2005;23:7518-7528. (Pubitemid 46291815)
69. Habal N, Gupta RK, Bilchik AJ, et al. TA90-1C, a new marker for advanced colon cancer. Ann Surg Oncol. 2000;7:352-356. (Pubitemid 30397476)
70. Sasatomi T, Suefuji Y, Matsunaga K, et al. Expression of tumor rejection antigens in colorectal carcinomas. Cancer. 2002;94:1636-1641. (Pubitemid 34241098)
71. Breivik J, Meling GI, Spurkland A, et al. K-ras mutations in colorectal cancer: relations to patient age, sex and tumour location. Br J Cancer. 1994;69:367-371. (Pubitemid 24046565)
72. Fossum B, Gedde-Dahl T, Breivik J, et al. P21-ras-peptide-specific T-cell responses in a patient with colorectal cancer. CD4+ and CD8+ T cells recognize a peptide corresponding to a common mutation. Int J Cancer. 1994;56:40-45. (Pubitemid 24044790)
73. Griffiths RW, Gilham DE, Dangoor A, et al. Expression of the 5T4 oncofetal antigen in renal cell carcinoma: a potential target for T-cell based immunotherapy. Br J Cancer. 2005;93:670-677. (Pubitemid 41486458)
74. Bui MH, Seligson D, Han KR, et al. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res. 2003;9:02-811.
75. Atkins M, McDermott D, Mier J, et al. Carbonic anhydrase IX (CAIX) expression predicts for renal cell cancer (RCC) patient response and survival to IL-2 therapy. Proc Am Soc Clin Oncol. 2004;23:383.
76. Lam JS, Leppert JT, Belldegrun AS, et al. Novel approaches in the therapy of metastatic renal cell carcinoma. World J Urol. 2005;23:202-212. (Pubitemid 41136043)
77. Mellitzer G, Xu Q, Willkinson DG, et al. Control of cell behavior by signaling through Eph receptors and Ephrins. Curr. Opin. Neurobiol. 2000;10:400-408. (Pubitemid 30389309)
78. Willkinson DG. Multiple roles of Eph receptors and Ephrins in neural development. Nat Rev Neurosci. 2001;2:155-164.
79. Knoll B, Zarbalis K, Wurst W, et al. A role for the EphA family in the topographic targeting of vomeronasal axons. Development. 2000;128: 895-906. (Pubitemid 32288200)
80. Tatsumi T, Herrem CJ, Olson WC, et al. Disease stage variation in CD4+ and CD8+ T-cell reactivity to the receptor tyrosine kinase EphA2 in patients with renal cell carcinoma. Cancer Res. 2003;63: 4481-4489. (Pubitemid 36951020)
81. Nicholaou T, Ebert L, Davis ID, et al. Directions in the immune targeting of cancer: lessons learned from the cancer-testis Ag NY-ESO-1. Immunol Cell Biol. 2006;84:303-317.
82. Avigan D. Dendritic cell-tumor fusion vaccines for renal cell carcinoma. Clin Cancer Res. 2004;10:6347S-6352S. (Pubitemid 39287490)
83. Hoover HC, Brandhorst JS, Peters LC, et al. Adjuvant active specific immunotherapy for human colorectal cancer: 6.5 year median follow-up of a phase III prospectively randomized trial. J Clin Oncol. 1993;11: 390-399. (Pubitemid 23071033)
84. Vermorken JB, Claessen AME, van Titeren H, et al. Active specific immunotherapy for stage II and stage III human colon cancer: a randomized trial. Lancet. 1999;353:345-350. (Pubitemid 29088160)
85. Harris JE, Ryan L, Benson A, et al. Results of the ECOG trial of autologous colon carcinoma vaccine. J Immunother. 1993;14:358.
86. Harris JE, Ryan L, Hoover HC, et al. Adjuvant active specific immunotherapy for stage II and III colon cancer with an autologous tumor cell vaccine: Eastern Cooperative Oncology Group Study E5283. J Clin Oncol. 2000;18:148-157. (Pubitemid 30036348)
87. Schulze T, Kemmner W, Weitz J, et al. Efficiency of adjuvant active specific immunization with Newcastle disease virus modified tumor cells in colorectal cancer patients following resection of liver metastases: results of a prospective randomized trial. Cancer Immunol Immunother. 2009;58:61-69.
88. Washburn B, Schirrmacher V. Human tumor cell infection by Newcastle disease virus leads to upregulation of HLA and cell adhesion molecules and to induction of interferons, chemokines and finally apoptosis. Int J Oncology. 2002;21:85-93.
89. Hartung G, Hofheinz RD, Dencausse Y, et al. Adjuvant therapy with edrecolomab versus observation in stage II colon cancer: a multicenter randomized phase III study. Onkologie. 2005;28:347-350. (Pubitemid 40827490)
90. Jocham D, Richter A, Hoffman L, et al. Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomized controlled trial. Lancet. 2004;363:594-599. (Pubitemid 38264176)
91. Wood C, Srivastava P, Bukowski R, et al. An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomized phase III trial. Lancet. 2008;372:145-154.
92. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunitys role in cancer suppression and promotion. Science. 2011; 331:1565-1570.